Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin

被引:83
作者
Senoo, Keitaro [1 ]
Proietti, Marco [1 ]
Lane, Deirdre A. [1 ]
Lip, Gregory Y. H. [1 ,2 ]
机构
[1] Univ Birmingham, Inst Cardiovasc Sci, City Hosp, Birmingham, W Midlands, England
[2] Aalborg Univ, Dept Clin Med, Aalborg Thrombosis Res Unit, Aalborg, Denmark
关键词
Anticoagulation; ATRIA; Bleeding; HAS-BLED; ORBIT; Risk assessment; VITAMIN-K ANTAGONISTS; ANTICOAGULATION; PREDICTION; MANAGEMENT; DISEASE; EVENTS;
D O I
10.1016/j.amjmed.2015.10.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES: Various bleeding risk prediction schemes, such as the Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized Ratio, Elderly, Drugs/alcohol (HAS-BLED), Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA), and Outcomes Registry for Better Informed Treatment (ORBIT) scores, have been proposed in patients with atrial fibrillation. We compared the relative predictive values of these bleeding risk scores for clinically relevant bleeding and the relationship of ATRIA and ORBIT scores to the quality of anticoagulation control on warfarin, as reflected by time in therapeutic range. METHODS: We conducted a post hoc ancillary analysis of clinically relevant bleeding and major bleeding events among 2293 patients receiving warfarin therapy in the AMADEUS trial. RESULTS: Only HAS-BLED was significantly predictive for clinically relevant bleeding, and all 3 risk scores were predictive for major bleeding. The predictive performance of HAS-BLED was modest, as reflected by c-indexes of 0.59 (P < .001) and 0.65 (P < .002) for clinically relevant bleeding and major bleeding, respectively. The HAS-BLED score performed better than the ATRIA (P = .002) or ORBIT (P = .001) score in predicting any clinically relevant bleeding. Only the HAS-BLED score was significantly associated with the risk for both bleeding outcomes on Cox regression analysis (any clinically relevant bleeding: hazard ratio, 1.85; 95% confidence interval, 1.43-2.40, P < .001; major bleeding: hazard ratio, 2.40; 95% confidence interval, 1.28-4.52; P = .007). There were strong inverse correlations of ATRIA and ORBIT scores to time in therapeutic range as a continuous variable (low risk ATRIA, r = -0.96; P = .003; ORBIT, r = -0.96; P = .003). Improvement in the predictive performance for both ATRIA and ORBIT scores for any clinically relevant bleeding was achieved by adding time in therapeutic range to both scores, with significant differences in c-indexes (P = .001 and P = .002, respectively), net reclassification improvement, and integrated discriminant improvement (both P < .001). CONCLUSIONS: All 3 bleeding risk prediction scores demonstrated modest predictive ability for bleeding outcomes, although the HAS-BLED score performed better than the ATRIA or ORBIT score. Significant improvements in both ATRIA and ORBIT score prediction performances were achieved by adding time in therapeutic range to both scores. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:600 / 607
页数:8
相关论文
共 19 条
[1]  
[Anonymous], 2015, EUR HEART J
[2]  
[Anonymous], EUR HEART J
[3]  
[Anonymous], ATR FIBR MAN ATR FIB
[4]   Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED Bleeding Risk-Prediction Scores in Patients With Atrial Fibrillation Undergoing Anticoagulation [J].
Apostolakis, Stavros ;
Lane, Deirdre A. ;
Guo, Yutao ;
Buller, Harry ;
Lip, Gregory Y. H. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (09) :861-867
[5]  
Bousser MG, 2008, LANCET, V371, P315, DOI 10.1016/S0140-6736(08)60168-3
[6]  
Camm AJ, 2012, EUROPACE, V14, P1385, DOI [10.1093/europace/eus305, 10.1093/eurheartj/ehs253]
[7]   Vitamin K antagonists in heart disease: Current status and perspectives (Section III) [J].
De Caterina, Raffaele ;
Husted, Steen ;
Wallentin, Lars ;
Andreotti, Felicita ;
Arnesen, Harald ;
Bachmann, Fedor ;
Baigent, Colin ;
Huber, Kurt ;
Jespersen, Jorgen ;
Kristensen, Steen Dalby ;
Lip, Gregory Y. H. ;
Morais, Joao ;
Rasmussen, Lars Hvilsted ;
Siegbahn, Agneta ;
Verheugt, Freek W. A. ;
Weitz, Jeffrey I. .
THROMBOSIS AND HAEMOSTASIS, 2013, 110 (06) :1087-1107
[8]   COMPARING THE AREAS UNDER 2 OR MORE CORRELATED RECEIVER OPERATING CHARACTERISTIC CURVES - A NONPARAMETRIC APPROACH [J].
DELONG, ER ;
DELONG, DM ;
CLARKEPEARSON, DI .
BIOMETRICS, 1988, 44 (03) :837-845
[9]   A New Risk Scheme to Predict Warfarin-Associated Hemorrhage The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study [J].
Fang, Margaret C. ;
Go, Alan S. ;
Chang, Yuchiao ;
Borowsky, Leila H. ;
Pomernacki, Niela K. ;
Udaltsova, Natalia ;
Singer, Daniel E. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 58 (04) :395-401
[10]   Net Clinical Benefit of Warfarin in Patients With Atrial Fibrillation A Report From the Swedish Atrial Fibrillation Cohort Study [J].
Friberg, Leif ;
Rosenqvist, Marten ;
Lip, Gregory Y. H. .
CIRCULATION, 2012, 125 (19) :2298-+